Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-100 in moderate/severe ARDS
NCT05938036Phase 2Active, not recruiting
- Sponsor
- Aqualung Therapeutics
- Start
- Dec 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of enamptcumab in acute respiratory distress syndrome (ARDS), sponsored by Aqualung Therapeutics. Started Dec 2023; status: active, not recruiting.
02
Drugs
enamptcumab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05938036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938036.